<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140333</url>
  </required_header>
  <id_info>
    <org_study_id>FAHG20130819</org_study_id>
    <secondary_id>GZMC201301</secondary_id>
    <nct_id>NCT02140333</nct_id>
  </id_info>
  <brief_title>Erlotinib 100mg or 150mg in Treating EGFR Mutation NSCLC Patients</brief_title>
  <official_title>Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutation Patients With Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 100mg erlotinib had similar effect
      compared with 150mg erlotinib in NSCLC patients with EGFR mutation in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In China it was confirmed that 150mg Erlotinib was effective in NSCLC patients wtih EGFR
      mutation, but reducing dose occurring in some patients because of the drug related
      side-effects. So we investigate that in Chinese patients with EGFR mutation whether low dose
      (100mg) Erlotinib had similar effect and low toxcities compared with standad dose (150mg)
      Erlotinib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The PFS time of patients</measure>
    <time_frame>2 years after the first treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The objective response rate of disease</measure>
    <time_frame>Patients will be followed for an expected average of 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival time of patients</measure>
    <time_frame>3 year after the first treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>NSCLC</condition>
  <condition>Egfr Mutation</condition>
  <arm_group>
    <arm_group_label>Erlotinib 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib 150mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erlotinib 150mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>100mg vs. 150mg</description>
    <arm_group_label>Erlotinib 100mg</arm_group_label>
    <arm_group_label>Erlotinib 150mg</arm_group_label>
    <other_name>tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The histological diagnosis of small cell lung cancer;(phase IIIB and IV)

          2. Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection
             method for the ARMS-PCR method, sequence method or Immunohistochemistry method)

          3. Never accept the anti-tumor therapy or have received treatment in patients with
             advanced illness patients;

          4. Never used EGFR inhibitors;

          5. Measurable disease by RECIST criteria;

          6. Male or female patients &gt;=18 years of age;

          7. ECOG karnofsky performance 0~3, life expectancy is greater than 12 weeks;

          8. Patient must be accessible for treatment and follow-up;-

        Exclusion Criteria:

          1. Previously used EGFR inhibitors

          2. Mix ingredients in patients with squamous cell carcinoma, small cell lung cancer;

          3. Allergic to erlotinib;

          4. Non-measurable lesions

          5. Pregnant or lactating women;

          6. Other researchers believe that does not fit into the group
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jianxing He, PhD</last_name>
    <phone>86-20-83062821</phone>
    <email>drjianxing.he@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yalei zhang, Dr.</last_name>
    <phone>86-20-83062821</phone>
    <email>yayazhang2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou medical university</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianxing he, PhD</last_name>
      <phone>86-20-83062821</phone>
      <email>drjianxing.he@gmail.com</email>
    </contact>
    <investigator>
      <last_name>jianxing he, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>October 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jianxing He</investigator_full_name>
    <investigator_title>The First Affiliated Hospital of Guangzhou Medical Univers</investigator_title>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>EGFR mutation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
